All the news Showing 10 of 27 articles from: New and experimental treatments for hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B Keith Alcorn / 14 November 2022 The experimental hepatitis B antiviral VIR-2218 shows potent activity against the virus when combined with either a monoclonal antibody that targets three steps in the hepatitis B lifecycle, or pegylated interferon, two studies ... Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five Keith Alcorn / 14 November 2022 Up to one in five people with hepatitis B treated with the experimental antiviral bepirovirsen achieved a sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA, a sign indicating the ... Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies Keith Alcorn / 29 June 2022 Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ... Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Keith Alcorn / 27 June 2022 People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ... Major hep B players Gilead and Vir join forces to find a cure Fierce Biotech / 18 January 2021 NASVAC therapeutic vaccine may lead to functional cure of hepatitis B Liz Highleyman / 17 November 2020 NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen levels and several study participants achieved a functional cure after ... Gilead immune modulator has modest effect on hepatitis B surface antigen Keith Alcorn / 01 September 2020 Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ... JNJ-3989 achieves sustained reductions in hepatitis B surface antigen Keith Alcorn / 29 August 2020 Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when combined with nucleoside analogue drugs, Professor Edward Gane of Auckland City Hospital, New ... GSK antisense agent for hepatitis B shows promise Keith Alcorn / 29 August 2020 An antisense agent, GSK-3228836, significantly reduced hepatitis B surface antigen levels in previously untreated people with chronic hepatitis B after three injections, an early phase trial reported this week at the Digital International ... Phase 1 clinical study begins for VTP-300 Immunotherapeutic for Hepatitis B patients Express Healthcare / 14 July 2020 ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive